Lumigan Information
Lumigan is a prescription medicine that is available as a Drops. Primarily, it is used for the treatment of Glaucoma.
The optimal dosage of Lumigan is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Refer to the dosage section for a detailed discussion.
The side effects typically associated with Lumigan include Eye itching, Eye irritation, Eye Burning. Besides the aforementioned side effects, there are other adverse effects of Lumigan as well, which are listed below. Normally, these side effects of Lumigan are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Lumigan's effect is Unknown during pregnancy and Unknown for lactating mothers. Warnings related to Lumigan's effects on the liver, heart and kidney, if any, have been listed below.
The section on Lumigan contraindications lists all such conditions.
Additionally, Lumigan may also adversely react with other medicines. Refer to the list below for further details.
You should also be aware that Lumigan is safe while driving, and is addiction.
Lumigan Benefits & Uses
Lumigan is used to treat the following -
Other Benefits
Lumigan Dosage & How to Take
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
Lumigan Side Effects
Based on research, the following side effects have been observed when Lumigan is used -
Common
- Eye itching
- Eye irritation
- Eye Burning
Lumigan Related Warnings
-
Is the use of Lumigan safe for pregnant women?
The effects of Lumigan on pregnant women are unknown since no research has been done to ascertain it yet.
Unknown -
Is the use of Lumigan safe during breastfeeding?
In the absence of any scientific study about the side effects of Lumigan in breastfeeding women, information on safety of Lumigan is unavailable.
Unknown -
What is the effect of Lumigan on the Kidneys?
Lumigan is not harmful for kidneys.
Safe -
What is the effect of Lumigan on the Liver?
There are no any side effects of Lumigan on the liver.
Safe -
What is the effect of Lumigan on the Heart?
Using Lumigan does not have any harmful effects on the heart.
Safe
Severe Interaction of Lumigan with Other Drugs
Lumigan should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
Lumigan Contraindications
If you are suffering from any of the following diseases, you should not take Lumigan unless your doctor advises you to do so -
- Uveitis
- Corneal Abrasion
- Kidney Disease
- Liver Disease
Frequently asked Questions about Lumigan
-
Is this Lumigan habit forming or addictive?
Lumigan is not addictive in nature.
No -
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Lumigan as it does not make you drowsy.
Safe -
Is it safe?
Yes, Lumigan does not show any kind of adverse effect.
Safe -
Is it able to treat mental disorders?
No, the use of Lumigan in mental disorders is not effective.
No
Lumigan Interactions with Food and Alcohol
-
Interaction between Food and Lumigan
Taking Lumigan with food is safe.
Safe -
Interaction between Alcohol and Lumigan
Information about the interaction of Lumigan and alcohol is not currently available because this topic has not been researched yet.
Unknown
See all substitutes for Lumigan
- Careprost Eye Drop - ₹482
- Lumigan 0.01% Eye Drop - ₹656
- Bimat LS Eye Drop - ₹203
- Lowprost Eye Drop - ₹266
- Lumigan 0.03% Eye Drop - ₹719
- Bimapix Eye Drop - ₹140
- Bimaday Eye Drop - ₹245
- Bimat Eye Drop - ₹281
- Careprost LS 0.01% Eye Drop 3ml - ₹379
- Gloria Eye Drop - ₹519
- Intaprost Eye Drop - ₹360
- Nuprost 0.03% Eye Drop - ₹292
- Xyprost Eye Drop - ₹265
- Bimatoprost Eye Drop - ₹210
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 227-228
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lumigan® (bimatoprost)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Latisse® (bimatoprost)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Bimatoprost Sandoz® (bimatoprost)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lumigan® Pf (bimatoprost)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 227-228
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lumigan® (bimatoprost)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Latisse® (bimatoprost)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Bimatoprost Sandoz® (bimatoprost)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lumigan® Pf (bimatoprost)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 227-228
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lumigan® (bimatoprost)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Latisse® (bimatoprost)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Bimatoprost Sandoz® (bimatoprost)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lumigan® Pf (bimatoprost)
